Stem Cell Therapeutics Corp. Granted Patent Portfolio and Expand Geographic Coverage of Key Stem Cell Technologies

CALGARY, ALBERTA--(Marketwire - Aug. 18, 2011) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") announces that it has received notification of the issuance of two new patents. The first entitled "Stimulation of Proliferation of Pluripotent Stem Cells through Administration of Pregnancy Associated Compounds" was granted by the United States Patent office; Patent number: 7,994,131. The second is entitled "Oligodendrocyte Production from Multipotent Neural Stem Cells" and was issued by the Japan Patent Office; Patent number: 4783013.

The first patent relates to the use of the pregnancy hormone human chorionic gonadotropin (hCG) to treat patients presenting with damaged or diseased heart cells.

The second patent adds yet another important territory to SCT's' family of patents relating to the use of granulocyte colony stimulating factor (GM-CSF) to treat white matter disorders by increasing the number of stem cells available to form CNS oligodendrocytes. White matter disorders include demyelinating diseases that include Multiple Sclerosis, Acute Disseminating Encephalomyelitis, Diffuse Cerebral Sclerosis, and Spinal Cord Injury.

Dr. Allen Davidoff, Chief Scientific Officer of Stem Cell Therapeutics Corp. commented "The rapid succession of granted patents in both neurology and now cardiology is a welcome development for Stem Cell Therapeutics Corp. Years of steadfast work by the Stem Cell Therapeutics scientists, staff and agents continues to build a valuable, world class patent portfolio. We are particularly excited by the first patent issued. This patent protects the newly discovered potential use of hCG for post heart attack recovery, and permits the development of new therapies in a large therapeutic market."

About Stem Cell Therapeutics Corp.:

Stem Cell Therapeutics Corp. is a public biotechnology company principally developing for commercialization drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The company's programs aim to repair brain and nerve function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as stroke, traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

Caution Regarding Forward-Looking Information:

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the "forward-looking statements"). These forward-looking statements relate to, among other things, SCT's objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to, the availability of capital, changes in capital markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, unproven markets for technologies in development, the cost and supply of raw materials, management of growth, effects of payors' willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading "Risk Factors" contained in SCT's 2010 annual information form. SCT cautions that the foregoing list of important factors that may affect future results is not exhaustive.

When relying on SCT's forward-looking statements to make decisions with respect to SCT, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of financing for research and development companies in addition to general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, SCT cannot provide assurance that actual results will be consistent with these forward-looking statements. SCT undertakes no obligation to update or revise any forward-looking statement.